- Biomerica's Fortel® Ulcer Test approved by UAE Ministry of Health for rapid detection of H. pylori infection.
- Rapid results in 10 minutes address significant public health need in UAE where infection rates exceed 50%.
- Approval enhances Biomerica's Middle East presence and complements existing diagnostic portfolio.
IRVINE, Calif., April 23, 2025 - Biomerica, Inc. (Nasdaq: BMRA), a leading provider of diagnostic solutions, has announced that its Fortel® Ulcer Test has received approval from the United Arab Emirates (UAE) Ministry of Health and Prevention. This approval allows for the distribution of the rapid point-of-care test for detecting Helicobacter pylori (H. pylori) infection across the UAE.
The Fortel® Ulcer Test is designed to deliver results within 10 minutes, offering a swift diagnosis of H. pylori, a bacterium associated with peptic ulcers, dyspepsia, and gastric cancer. H. pylori infection is particularly significant in the UAE, where studies indicate infection rates exceed 50%, underscoring the public health importance of this approval.
The World Health Organization (WHO) classifies H. pylori as a Class 1 carcinogen, attributing around 80% of gastric cancer cases globally to this infection, which is the third leading cause of cancer-related deaths worldwide. Therefore, the rapid detection capabilities of Biomerica's test could facilitate early intervention and potentially improve patient outcomes by preventing the progression of severe complications.
With this regulatory milestone, Biomerica is set to expand its market presence in the Middle East further, following the successful regional launches of other diagnostic products. The company is collaborating with UAE-based distributors to ensure the Fortel® Ulcer Test is readily available throughout the country.
